In today’s briefing:
- Latest Development & Potential First Target of Mandatory Tender Offer in Korea
- InMed Pharmaceuticals, Inc. – White Paper Highlights Attributes of CBC
- Insulet Corporation: Launch of Omnipod 5 & Other Major Developments
- West Pharmaceutical Services: What Is Their Biggest Competitive Advantage? – Major Drivers
Latest Development & Potential First Target of Mandatory Tender Offer in Korea
- Considering the progress of the legislative process at this juncture, the effective date could be as early as the end of this year or, at the latest, early next year.
- Ilooda (164060 KS) will likely become the first case. A tender offer at ₩11,000 (a 30% premium to the current price) per share for 14%+1 share may greet us.
- There is sufficient value in monitoring the interaction between the offer structure and stock price movement in the context of the first application of a mandatory tender offer in Korea.
InMed Pharmaceuticals, Inc. – White Paper Highlights Attributes of CBC
Therapeutic attributes of CBC highlighted in white paper. InMed Pharmaceuticals’ commercial subsidiary BayMedica released a white paper, which collates a curated collection of scientific research on the physiological and potential therapeutic effects of cannabichromene (CBC).
CBC is BayMedica’s lead product sold to the health & wellness sector.
CBC demonstrates potent anti-inflammatory effects. Since the discovery of the endocannabinoid system (ES) in 1988, there has been mounting research into the interaction of cannabinoids with ES receptors, which regulate critical human functions, such as temperature, appetite, blood sugar, sleep, memory, emotional processing, pain, and inflammatory and immune responses.
Insulet Corporation: Launch of Omnipod 5 & Other Major Developments
- Insulet Corporation exceeded analyst expectations in terms of revenue as well as earnings.
- The company’s revenue for the second quarter surpassed its projections, growing by 33% overall at Omnipod, including 41% in the United States.
- During the second quarter, Insulet made significant progress in its clinical and innovation programs.
West Pharmaceutical Services: What Is Their Biggest Competitive Advantage? – Major Drivers
- West Pharmaceutical Services delivered mixed results for the previous quarter, with revenues below the analyst consensus.
- Sales price increases provided $43.1 million or 5.6 percentage points of growth in the quarter.
- The base Proprietary goods business expanded by the mid-teens and was the main driver of the second quarter achievement.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
